Palo Alto, Calif.-based StemCells announced a licensing deal giving the
U.K.'s ReNeuron rights to its technology for using human neural stem
cells. The U.K. firm is testing a stem cell therapy for stroke and
working to develop stem cell treatments for diabetes, Parkinson's
disease, Huntington's disease and certain eye disorders.

Full Story:

Related Summaries